CN100528156C - 在疼痛治疗中成瘾的预防 - Google Patents

在疼痛治疗中成瘾的预防 Download PDF

Info

Publication number
CN100528156C
CN100528156C CNB028098277A CN02809827A CN100528156C CN 100528156 C CN100528156 C CN 100528156C CN B028098277 A CNB028098277 A CN B028098277A CN 02809827 A CN02809827 A CN 02809827A CN 100528156 C CN100528156 C CN 100528156C
Authority
CN
China
Prior art keywords
gaba
analgesic
days
medicament
gvg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB028098277A
Other languages
English (en)
Chinese (zh)
Other versions
CN1531431A (zh
Inventor
史蒂芬·L·笛威
乔纳森·D·布鲁迪
小查尔斯·R·阿西比
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Brookhaven Science Associates LLC
Original Assignee
Brookhaven Science Associates LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brookhaven Science Associates LLC filed Critical Brookhaven Science Associates LLC
Publication of CN1531431A publication Critical patent/CN1531431A/zh
Application granted granted Critical
Publication of CN100528156C publication Critical patent/CN100528156C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNB028098277A 2001-05-14 2002-04-08 在疼痛治疗中成瘾的预防 Expired - Fee Related CN100528156C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/853,548 2001-05-14
US09/853,548 US20020187996A1 (en) 2001-05-14 2001-05-14 Prevention of addiction in pain management

Publications (2)

Publication Number Publication Date
CN1531431A CN1531431A (zh) 2004-09-22
CN100528156C true CN100528156C (zh) 2009-08-19

Family

ID=25316324

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB028098277A Expired - Fee Related CN100528156C (zh) 2001-05-14 2002-04-08 在疼痛治疗中成瘾的预防

Country Status (21)

Country Link
US (3) US20020187996A1 (enExample)
EP (1) EP1392301B1 (enExample)
JP (1) JP2004534029A (enExample)
KR (1) KR20040020054A (enExample)
CN (1) CN100528156C (enExample)
AT (1) ATE473001T1 (enExample)
AU (1) AU2002342533B2 (enExample)
BR (1) BR0209613A (enExample)
CA (1) CA2446639C (enExample)
CZ (1) CZ20033380A3 (enExample)
DE (1) DE60236927D1 (enExample)
ES (1) ES2348637T3 (enExample)
HR (1) HRP20030892A2 (enExample)
HU (1) HUP0402326A3 (enExample)
IL (1) IL158762A0 (enExample)
MX (1) MXPA03010407A (enExample)
NO (1) NO331509B1 (enExample)
NZ (1) NZ529614A (enExample)
PL (1) PL368505A1 (enExample)
WO (1) WO2002091990A2 (enExample)
YU (1) YU89003A (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001281746C1 (en) * 2000-07-31 2010-09-09 ISTITUTO GENTILI S.r.l. Fentanyl composition for nasal administration
DE10141650C1 (de) 2001-08-24 2002-11-28 Lohmann Therapie Syst Lts Transdermales Therapeutisches System mit Fentanyl bzw. verwandten Substanzen
US20050043345A1 (en) * 2003-08-22 2005-02-24 Pfizer Inc Pharmaceutical composition for the prevention and treatment of addiction in a mammal
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
CN105497896A (zh) * 2015-03-31 2016-04-20 苏州大学 一种肿瘤耐药的靶点及其应用
JP7720911B2 (ja) 2020-12-04 2025-08-08 ラボラトリオス シラネス、エセ．ア．デ セ．べ． 痛みに対するオピオイド鎮痛薬と抗てんかん薬のコーティングされた安定な固体医薬組成物
US11977085B1 (en) 2023-09-05 2024-05-07 Elan Ehrlich Date rape drug detection device and method of using same

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6541520B1 (en) * 1998-08-05 2003-04-01 Brookhaven Science Associates Treatment of addiction and addiction-related behavior
US6057368A (en) * 1998-08-05 2000-05-02 Brookhaven Science Associates Llc Treatment of addiction and addiction-related behavior

Also Published As

Publication number Publication date
HRP20030892A2 (en) 2005-08-31
US20020187996A1 (en) 2002-12-12
CN1531431A (zh) 2004-09-22
HUP0402326A3 (en) 2008-04-28
BR0209613A (pt) 2004-12-07
JP2004534029A (ja) 2004-11-11
EP1392301A4 (en) 2004-07-14
NZ529614A (en) 2006-08-31
NO20035038D0 (no) 2003-11-13
IL158762A0 (en) 2004-05-12
US6939876B2 (en) 2005-09-06
US20030134868A1 (en) 2003-07-17
KR20040020054A (ko) 2004-03-06
WO2002091990A3 (en) 2003-03-27
AU2002342533B2 (en) 2007-07-05
WO2002091990A2 (en) 2002-11-21
CA2446639C (en) 2010-11-02
HUP0402326A2 (hu) 2005-02-28
ES2348637T3 (es) 2010-12-10
NO331509B1 (no) 2012-01-16
MXPA03010407A (es) 2004-05-05
EP1392301A2 (en) 2004-03-03
EP1392301B1 (en) 2010-07-07
US20030004176A1 (en) 2003-01-02
DE60236927D1 (de) 2010-08-19
PL368505A1 (en) 2005-04-04
CA2446639A1 (en) 2002-11-21
ATE473001T1 (de) 2010-07-15
CZ20033380A3 (cs) 2005-03-16
YU89003A (sh) 2006-08-17

Similar Documents

Publication Publication Date Title
US5578645A (en) Methods and compositions for treating acute or chronic pain and drug addiction
TWI243674B (en) Use of gamma vinylGABA (GVG) or a pharmaceutically acceptable salt thereof, or an enantiomer or a racemic mixture thereof
CN102302492A (zh) 诱导哺乳动物镇痛应答的方法和组合物
CN100528156C (zh) 在疼痛治疗中成瘾的预防
JP2017506244A (ja) ノルイボガイン及び関連化合物を用いた治療方法
Colvin et al. Differential effects of intra-ventral tegmental area ghrelin and glucagon-like peptide-1 on the stimulatory action of D-amphetamine and cocaine-induced ethanol intake in male Sprague Dawley rats
Akuzawa et al. Effect of ASP8062 on morphine self-administration and morphine-induced respiratory suppression in monkeys
Skoogh et al. Barbiturates depress vagal motor pathway to ferret trachea at ganglia
US20060177381A1 (en) Opiopathies
Wei et al. Cebranopadol reduces cocaine self-administration in male rats: Dose, treatment and safety consideration
CN111214469B (zh) 预防和治疗慢性疼痛的化合物及其应用
AU2002342533A1 (en) Prevention of addiction in pain management
EP2007388B1 (en) Opiopathies
CN114159450B (zh) 原人参二醇类化合物在治疗疼痛和成瘾物质躯体依赖、精神依赖和成瘾的用途
CN112569237A (zh) 伊马替尼及其衍生物与尼古丁或其类似物联用或复方在防治尼古丁成瘾与复吸中的应用
Glaubach Sulfapyridine potentiation of narcotic and toxic effects of papaverine in rats and rabbits
Yadav Pharmacology & toxicology
US20240277697A1 (en) Methods of treating or preventing conditions associated with opiate withdrawal or opiate relapse
JP2020526500A (ja) 治療方法及びその剤形
CN115969850A (zh) 小檗胺在制备镇痛药物中的应用
Karandikar et al. Comparative study of CNS effects of opium in homeopathic potencies with pentazocine in mice
Wikler DR. ABRAHAM WIKLER, Associate Director, Addiction Research Center, 1942-63
Wikler Neurophysiological and Neuropsychiatric Aspects of Opioid
Dumke Newer agents for the anesthesiologist
Madison The effect of a neuropeptide FF receptor subtype-selective compound on morphine tolerance

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20090819

Termination date: 20110408